Evidence map›Paper›PMID 42799871›Full record

ArticleAnnals of hematology2026

The SPIZ study: rationale and protocol of a randomized controlled trial to optimize interdisciplinary care of patients following cellular therapy through a digitally supported, cross-regional and cross-sectoral care model.

Martin M K Schneider, Gabriele Müller, Sabrina Herbst, Julia Slesaczeck, Roman Schmädig, Franziska Schmidt, Thomas Illmer, Lynn Leppla, Sabine Valenta, Sabina De Geest and 13 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Martin M K SchneiderDepartment of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Gabriele MüllerCenter for Evidence-Based Healthcare, Faculty of Medicine, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Sabrina HerbstCenter for Evidence-Based Healthcare, Faculty of Medicine, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Julia SlesaczeckCenter for Evidence-Based Healthcare, Faculty of Medicine, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Roman SchmädigDirectorate Nursing, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Franziska SchmidtDepartment of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Thomas IllmerPrivate Practice Hematology and Oncology, Dresden, Germany.
Lynn LepplaDepartment of Medicine I, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg im Breisgau, Germany.
Sabine ValentaInstitute of Nursing Science, Department Public Health, Faculty of Medicine, University of Basel, Basel, Switzerland.
Sabina De GeestInstitute of Nursing Science, Department Public Health, Faculty of Medicine, University of Basel, Basel, Switzerland.
Alexandra TeynorInstitute for Agile Software Development, Technical University of Applied Sciences Augsburg, Augsburg, Germany.
Markus WolfienInstitute for Medical Informatics and Biometry, Faculty of Medicine, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Alice ErnstAOK PLUS, Sternplatz 7, 01067, Dresden, Germany.
Lara BischofDepartment of Hematology and Cellular Therapy, Hemostaseology and Infectious Diseases, University Hospital Leipzig, Leipzig, Germany.
Jochen SchmittCenter for Evidence-Based Healthcare, Faculty of Medicine, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Mathias HänelDepartment of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany.
Klaus H MetzelerDepartment of Hematology and Cellular Therapy, Hemostaseology and Infectious Diseases, University Hospital Leipzig, Leipzig, Germany.
Uwe PlatzbeckerDepartment of Hematology and Cellular Therapy, Hemostaseology and Infectious Diseases, University Hospital Leipzig, Leipzig, Germany.
Vladan VučinićDepartment of Hematology and Cellular Therapy, Hemostaseology and Infectious Diseases, University Hospital Leipzig, Leipzig, Germany.
Johannes ScheteligDepartment of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Martin BornhäuserDepartment of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Jan Moritz MiddekeDepartment of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Katharina Egger-HeidrichDepartment of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany. Katharina.Egger-Heidrich@ukdd.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplantation (alloHCT) and chimeric antigen receptor T (CAR T)-cell therapy represent established therapeutic modalities for selected hematologic malignancies but are associated with substantial morbidity, high healthcare costs, and a considerable risk of severe complications, including death. This necessitates specialized and continuous post-treatment care, which is currently insufficiently standardized and still largely delivered predominantly through in-person and nonintegrated processes. We aimed to develop a comprehensive and innovative post-treatment care program for patients after alloHCT and CAR T-cell therapy based on an interdisciplinary, digitally supported, cross-regional and, cross-sectoral approach, and to evaluate its effectiveness in a randomized controlled trial (RCT). Developed by a multidisciplinary team, the intervention involves case managers and home visits by onco nurses, supported by digital components. These include patient-reported monitoring of vital signs and symptoms via a mobile application, video consultations, and virtual case conferences with community-based hematologists. The evaluation of effectiveness includes both quantitative outcomes, such as mortality and rehospitalization rates, and qualitative data derived from semi-structured interviews. The required ethics approvals were obtained in due time, and the three study centers were successfully initiated in 2024. As of January 2026, recruitment has been completed, and a total of 306 patients were successfully enrolled and randomized in a 1:1 ratio to receive either the SPIZ intervention or routine care. Funded and supported by the Federal Joint Committee (G-BA), a positive evaluation could facilitate the integration of the proposed care model into routine clinical practice, thereby strengthening post-treatment care for patients undergoing cellular therapy across Germany.

Indexed as

AftercareHematologic NeoplasmsHematopoietic Stem Cell TransplantationImmunotherapy, AdoptivePatient Care TeamFemaleHumansMaleMulticenter Studies as TopicRandomized Controlled Trials as TopicTelemedicineAllogeneic hematopoietic cell transplantationCAR T-cell therapydigital healthpost-treatment care

Identifiers

PMID42799871
PMCPMC13615902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.